Pellanda Alessandra Franzetti, De Bari Berardino, Deniaud-Alexandre Elisabeth, Krengli Marco, Van Houtte Paul, Richetti Antonella, Villà Salvador, Goldberg Hadassah, Szutowicz-Zielińska Ewa, Bolla Michel, Rutten Heidi, Van Eijkeren Marc, Poortmans Philip, Henke Guido, Anacak Yavuz, Chan Steve, Landmann Christine, Kirkove Carine, Scandolaro Luciano, Bernier Jacques, Mirimanoff René-Olivier, Ozsahin Mahmut
Centre Hospitalier Universitaire Vaudois (CHUV), 1011 Lausanne, Switzerland.
Clinica Luganese Moncucco, 6903 Lugano, Switzerland.
Chin J Cancer Res. 2017 Dec;29(6):521-532. doi: 10.21147/j.issn.1000-9604.2017.06.06.
Primary uterine leiomyosarcomas (ULMS) are rare, and the optimal treatment is controversial. We aimed to assess the outcome and prognostic factors in a multicenter population of women treated for primary ULMS.
We retrospectively collected data of 110 women treated in 19 institutions of the Rare Cancer Network (RCN). Inclusion criteria consisted of a pathology report confirming the diagnosis of ULMS, aged 18-80 years, complete International Federation of Gynecology and Obstetrics (FIGO) stage information, complete information on treatment, and a minimum follow-up of 6 months. Local control (LC) and locoregional control (LRC), overall survival (OS) and disease-free survival (DFS) rates were computed using the Kaplan-Meier method. Univariate analysis was implemented using the log rank test, and multivariate analysis using the Cox model.
All patients underwent surgery. Seventy-five patients (68%) received adjuvant radiotherapy (RT), including brachytherapy in 18 (16%). Seventeen patients (15%) received adjuvant chemotherapy. Median follow-up was 58 (range, 6-240) months. Five-year OS and DFS rates were 50% and 34%, and LC and LRC rates were 88% and 72%, respectively. On multivariate analysis, independent favorable prognostic factors were younger age, FIGO stage I, small tumor size, previous uterine disease, and no vascular invasion for OS and DFS. FIGO stage was the only favorable factor influencing LRC. Adjuvant local or systemic treatments did not improve the outcomes. Eight patients treated with RT presented a grade 3 acute toxicity, and only one patient with grade 3 late toxicity.
In this large population of primary ULMS patients, we found good results in terms of LC and LRC. Nevertheless, OS remains poor, mainly due to the occurrence of distant metastases. An early diagnosis seemed to improve the prognosis of the patients. Adjuvant local or systemic treatments, or more aggressive surgical procedures such as the Wertheim procedure, did not seem to impact the outcome.
原发性子宫平滑肌肉瘤(ULMS)较为罕见,其最佳治疗方案存在争议。我们旨在评估多中心原发性ULMS女性患者的治疗结局及预后因素。
我们回顾性收集了罕见癌症网络(RCN)19个机构中110例女性患者的数据。纳入标准包括病理报告确诊为ULMS、年龄在18 - 80岁之间、完整的国际妇产科联盟(FIGO)分期信息、完整的治疗信息以及至少6个月的随访。采用Kaplan-Meier法计算局部控制(LC)和区域控制(LRC)、总生存(OS)和无病生存(DFS)率。使用对数秩检验进行单因素分析,使用Cox模型进行多因素分析。
所有患者均接受了手术。75例患者(68%)接受了辅助放疗(RT),其中18例(16%)接受了近距离放疗。17例患者(15%)接受了辅助化疗。中位随访时间为58(范围6 - 240)个月。5年OS和DFS率分别为50%和34%,LC和LRC率分别为88%和72%。多因素分析显示,独立的有利预后因素包括年龄较小、FIGO I期、肿瘤体积小、既往子宫疾病以及OS和DFS无血管侵犯。FIGO分期是影响LRC的唯一有利因素。辅助局部或全身治疗并未改善结局。8例接受RT治疗的患者出现3级急性毒性,仅1例患者出现3级晚期毒性。
在这一大量原发性ULMS患者群体中,我们在LC和LRC方面取得了良好结果。然而,OS仍然较差,主要是由于远处转移的发生。早期诊断似乎可改善患者预后。辅助局部或全身治疗,或更激进的手术操作如韦特海姆手术,似乎并未影响结局。